Trifork Holding AG (“Trifork”) upgrades outlook for the 2022 financial results from what was previously communicated on 16 March 2022 in connection with the announcement of Trifork’s 2021 financial results:
- Revenue target for the financial year 2022 is increased to EURm 180-185 from EURm 175-180.
- Trifork Segment adjusted EBITDA target (excluding Trifork Labs and special items) for the financial year 2022 is increased to EURm 30.5-33.0 from EURm 29.5-32.0.
- Trifork Group EBIT target for the financial year 2022 is increased to EURm 16.5-19.0 from EURm 15.5-18.0.
The upgraded outlook for 2022 is based on an increased operational performance and organic growth in our Digital Health Business Area and a strong inflow of new or renewed framework agreements with existing customers.
As announced in Company announcement no. 5 / 2022 on March 28, Trifork won a strategic tender based on a joint SAP-Trifork cooperation and signed a letter of intent with a Swiss healthcare customer in March. Today, a final agreement has been signed between Swiss-based Bluespace Ventures AG and Trifork, thus making Trifork the Lead Technology Partner to provide advanced healthcare technology.
This is a milestone in Trifork’s effort to bring Digital Health products and services to more markets and also has a positive impact on our financial outlook.
Mid-term targets are maintained. Over a three-year period, Trifork Group targets annual average revenue growth of 15-25% with organic revenue growth of 10-15% on average per year over the same period.